These findings lead the authors to the conclusion that the single application of an sEH-I or a PPARγ modulator is beneficial, but in regard to the multi disease characteristics of the MetS, the combination is even superior (Imig et al., 2012). This evidence concerns the gene PPARG and metabolic syndrome.